Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection

March 26, 2025 updated by: Alexandria University

The Effect of Intrabronchial Therapy with Gentamycin and Dexamethason After Bronchoscopic Airway Clearance in Exacerbation of Bronchiectasis

Fiberoptic Bronchoscopic Removal of Secretions and Antibiotic Injection

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

fiberoptic bronchoscopic injection of dexamethason and gentamicin after airway clearance

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Alexandria, Egypt, 11511
        • Chest Department -Faculty of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

1- Adult subjects. 2- Male and female subjects are enrolled. 3- patients with NCFB confirmed by chest high-resolution computed tomography (HRCT) 4- patients needing antibiotic treatment at the hospital due to exacerbation 5- Patients who underwent AC by bronchoscopy at the hospital.

-

Exclusion Criteria:

1- Uncooperative subjects. 2- Unwilling to participate. 3- Inability to lie on the back with raised arms over the head for HRCT. 4- Presence of cystic pulmonary fibrosis; 5- Patients with active pulmonary tuberculosis; 6- Those awaiting surgery; 7- Patients who underwent interventional therapy for hemoptysis; those with allergic bronchopulmonary aspergillosis (ABPA); 8- Patients who did not undergo bronchoscopy for different reasons or combined with lung cancer.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: fiberoptic bronchoscopy in one group
Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
Procedure: Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dyspnea Borg Scale
Time Frame: one month
improvement in the scale of dyspnea before and after the procedure
one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alexandria University

Investigators

  • Principal Investigator: mohamed sabry eltarhony, lecturer, Alexandria University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2024

Primary Completion (Actual)

January 15, 2025

Study Completion (Actual)

January 20, 2025

Study Registration Dates

First Submitted

March 26, 2025

First Submitted That Met QC Criteria

March 26, 2025

First Posted (Actual)

April 2, 2025

Study Record Updates

Last Update Posted (Actual)

April 2, 2025

Last Update Submitted That Met QC Criteria

March 26, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • bronchiectasis FOB

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

i will do it after being accepted from the ethics committee

Study Data/Documents

  1. Study Protocol
    Information identifier: msabry776@yahoo.com
    Information comments: very good

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiectasis Adult

Clinical Trials on Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe